Agendia and Partners Receive $6.8 million from European Commission to Study Targeted Therapies for Colorectal Cancer
IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, Inc. and Read More
Agendia’s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium
Satellite Symposium and Dinner Presentation Will Offer Latest Insights on Genomic Read More
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Read More
Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens
Researchers Present Data at Breast Cancer Symposium Showing MammaPrint/BluePrint Can Identify Read More
Agendia Board of Directors Appoints Mark R. Straley as New CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader Read More
NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis
Respected Panel Cites RASTER, the Only Published Prospective Outcome Data Read More
Agendia Announces Recommendation of MammaPrint in Germany’s AGO Guidelines, at St. Gallen International Breast Cancer Conference
Company Also Highlights FDA Clearance of MammaPrint in FFPE IRVINE, Read More
Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference
Results of the NBRST Trial Using Agendia’s BluePrint 80-Gene Molecular Read More
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients
PUBLICATION: Breast Care 2015;10:118-122 https://doi.org/10.1159/000376562. AUTHORS: Shimizu H., Horimoto Y., Read More
Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test
FDA Decision Covers Use of MammaPrint in FFPE for the 70-Gene Read More
